Fig. 9

Analysis of refractory outcomes based on 2-year cumulative and daily average MMI dosage. A 2-year cumulative MMI dosage. B 2-year daily average MMI dosage. MMI methimazole. **P < 0.01; ***P < 0.001. High: High Predicted Risk Group (≥ 63%), Class III + and IV + in Model B and Class IV + in Model C. Medium: Medium Predicted Risk Group (36–63%), Class II + in Model B and Class III + in Model C. Low: Low Predicted Risk Group (< 44%), Class I + in Model B and Class I + and II + in Model C